Ribometrix Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$12M
- Investors
-
13
Ribometrix General Information
Description
Operator of a biotechnology company intended to develop small-molecule therapeutics that modulate ribonucleic acid biology. The company leverages expertise in three-dimensional Ribonucleic acid structural analysis to identify novel small molecules that inhibit the production of disease-associated proteins, proprietary ribonucleic acid structure determination, state-of-the-art ribonucleic acid tools and technologies, and complementary artificial intelligence and machine learning capabilities to directly target and modulate ribonucleic acid biology, enabling researchers to analyze and understand the role that ribonucleic acid structure plays in biological processes and disease.
Contact Information
Website
www.ribometrix.comCorporate Office
- 8 Davis Drive
- Suite 120
- Durham, NC 27713
- United States
Corporate Office
- 8 Davis Drive
- Suite 120
- Durham, NC 27713
- United States
Ribometrix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 06-Sep-2023 | $12M | Completed | Pre-Clinical Trials | ||
| 8. Later Stage VC (Series A1) | 26-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 7. Early Stage VC (Series A) | 13-Nov-2018 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 15-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 01-Jan-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Debt - General | 20-Jun-2016 | Completed | Startup | |||
| 3. Grant | 01-Jan-2016 | Completed | Startup | |||
| 2. Corporate | 01-Jan-2015 | $100K | $100K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2014 | Completed | Startup |
Ribometrix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A | ||||||||
| Series 1 | 6,675,574 | $0.001000 | $1.12 | $1.12 | 1x | $1.12 | 19.75% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ribometrix Comparisons
Industry
Financing
Details
Ribometrix Competitors (15)
One of Ribometrix’s 15 competitors is Remix Therapeutics, a Venture Capital-Backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Remix Therapeutics | Venture Capital-Backed | Watertown, MA | ||||
| Anima Biotech | Formerly VC-backed | Bernardsville, NJ | ||||
| STORM Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Arrakis Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
| Biosplice Therapeutics | Private Equity-Backed | San Diego, CA |
Ribometrix Patents
Ribometrix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025120599-A1 | Methods of using eif4e inhibitors for treating cancer | Inactive | 08-Dec-2023 | ||
| WO-2025101516-A1 | Methods of using eif4e inhibitors for treating cancer | Inactive | 06-Nov-2023 | ||
| US-20240246918-A1 | Compounds and compositions as eif4e inhibitors and the uses thereof | Pending | 10-Nov-2022 | ||
| AU-2023375675-A1 | Compounds and compositions as eif4e inhibitors and uses thereof | Pending | 10-Nov-2022 | ||
| AU-2023375677-A1 | Compounds and compositions as eif4e inhibitors and uses thereof | Pending | 10-Nov-2022 | C07D239/90 |
Ribometrix Signals
Ribometrix Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gray Ventures | Venture Capital | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| Illumina Ventures | Venture Capital | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| Pappas Capital | Venture Capital | Minority |
Ribometrix FAQs
-
When was Ribometrix founded?
Ribometrix was founded in 2014.
-
Where is Ribometrix headquartered?
Ribometrix is headquartered in Durham, NC.
-
What is the size of Ribometrix?
Ribometrix has 21 total employees.
-
What industry is Ribometrix in?
Ribometrix’s primary industry is Discovery Tools (Healthcare).
-
Is Ribometrix a private or public company?
Ribometrix is a Private company.
-
What is Ribometrix’s current revenue?
The current revenue for Ribometrix is .
-
How much funding has Ribometrix raised over time?
Ribometrix has raised $57.5M.
-
Who are Ribometrix’s investors?
Gray Ventures, Amgen Ventures, Illumina Ventures, M Ventures, and Pappas Capital are 5 of 13 investors who have invested in Ribometrix.
-
Who are Ribometrix’s competitors?
Remix Therapeutics, Anima Biotech, STORM Therapeutics, Arrakis Therapeutics, and Biosplice Therapeutics are some of the 15 competitors of Ribometrix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process